Specifically, the court has denied petitions requesting appeal from Applera concerning six Enzo patents asserted against Applera and Tropix, thus allowing Enzo’s infringement case to go forward.
The alleged infringing products include Applera’s Applied Biosystems’ DNA sequencing products and systems as well as services.
“This ruling paves the way for Enzo to establish infringement by defendants’ sequencing products and systems, including its TaqMan genotyping and gene expression assays, and the gene expression microarrays used with its Expression Array System,” stated Dr Elazar Rabbani, Enzo’s CEO.
Enzo Biochem’s proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world.